Pharma Training Programs

Advance Your Scientific and Regulatory Competence

Empowering pharma professionals through expert-led training on ICH guidelines, impurity assessment, nitrosamine control and regulatory compliance.
Ultra Bio Instruments offers specialized training programs that equip professionals with the skills and regulatory insight required to meet evolving global standards.  Our modules are curated by domain experts with deep experience in impurity control, regulatory strategy and analytical sciences.  Each program combines scientific theory with real-world application – ensuring knowledge that is both compliant and practical.

Customized Training Sessions by Subject Matter Experts

Mutagenic Impurities and ICH M7 Requirements

• Understanding impurity classification, (Q)SAR analysis, and acceptable limit determination.
• Regulatory updates and current challenges.

Nitrosamine impurities in API and dosage forms

• Identification, evaluation, and mitigation aligned with latest global guidance
• Safety evaluation and toxicity assessment
• Documentation for regulatory submission

Extractables & Leachable Qualification (ICH Q3E)

• Regulatory requirements and scientific context.
• Guidance on experimental design, data interpretation
• Analytical techniques used for E&L studies

Elemental Impurities Assessment (ICH Q3D)

• Identification, risk assessment, and control of impurities as per ICH guidelines
• Understanding permitted daily exposure (PDE) values,

Forced degradation Studies

• Comprehensive forced degradation studies for API and dosage forms.
• Degradation characterization. Analytical strategies

Excipient Qualification

• Methods for qualifying specific levels of excipients in drug products
• Technical standards needed to approve and manage excipient suppliers.

Training Format

Flexible, Practical & Impact Oriented

Who should Attend

Ideal for Professionals across Key functions

Why Choose Us

Request a Tailored Training Program

We customize training to align with your organization’s needs, regulatory priorities, and product portfolio.